{
    "clinical_study": {
        "@rank": "92591", 
        "acronym": "LIDOSP", 
        "arm_group": [
            {
                "arm_group_label": "lidocaine", 
                "arm_group_type": "Active Comparator", 
                "description": "Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, prospective, randomized, placebo-controlled, double-blind,\n      two-parallel groups study comparing lidocaine (experimental group) to  placebo (control\n      group). The study protocol was elaborated using the recommendations of the Consolidated\n      Standards of Reporting Trials (CONSORT) Statement."
        }, 
        "brief_title": "Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Pain With Neuropathic Component"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient aged 18 years or older\n\n          -  Patient suffering from cancer pain refractory to standard opiates (numeric pain\n             intensity scale NPIS >=4/10 after 24 hours of continuous intravenous morphine or\n             oxycodone administration [SOR 2002, analgesics drugs for adults cancer nociceptive\n             pain]), regardless of the nature of the primary cancer]\n\n          -  Patient suffering from cancer neuropathic or mixed pain (DNA survey score> = 4\n             [Bouhassira 2004])\n\n          -  Patient receiving palliative care as defined by French Society of Palliative and\n             Support Care [Charte des Soins Palliatifs, 1996, Act No. 99-477 of 9 June 1999 to\n             guarantee the right of access to palliative care] according to the definition of the\n             World Health Organization (WHO) [World Health Organization. WHO's pain ladder.\n             http://www.who.int/cancer/palliative/painladder/en/. Accessed December 9.2011]\n\n          -  Patient with histological diagnosis of cancer, locally advanced or metastatic disease\n\n          -  Patient without curative cancer treatment, and with or without palliative anticancer\n             treatment\n\n          -  Patient hospitalized in a specific palliative care unit\n\n          -  Patient with an estimated survival higher than 48 hours (physician estimation)\n             Patient providing written informed consent for participation prior to any study\n             procedures.\n\n        Exclusion Criteria:\n\n          -  Patient with a known hypersensitivity to lidocaine\n\n          -  Patient with a history of porphyria, arrhythmias, disorders of atrioventricular\n             conduction requiring permanent pacing not yet realized, uncontrolled epilepsy,\n             uncontrolled hypertension\n\n          -  Patient with hematologic malignancy, abnormal renal, hepatic and cardiac functions\n\n          -  Patient with a altered sleepiness (Epworth scale score \u2264 16)\n\n          -  Patient with altered cognitive function (TELECOM scale score> 11) [Ars\u00e8ne 2000]\n\n          -  Patient not native French speaker Patient defined as vulnerable subject (minor\n             subject, pregnant or nursing woman, subject freedom deprived)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137954", 
            "org_study_id": "2013-50"
        }, 
        "intervention": [
            {
                "arm_group_label": "lidocaine", 
                "intervention_name": "Lidocaine", 
                "intervention_type": "Drug", 
                "other_name": "Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lidocaine", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cancer", 
            "pain"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "sebastien.salas@ap-hm.fr", 
                "last_name": "Sebastien Salas, MD", 
                "phone": "+3349138408"
            }, 
            "facility": {
                "address": {
                    "city": "Marseille", 
                    "country": "France", 
                    "zip": "13005"
                }, 
                "name": "- Service d'Oncologie M\u00e9dicale et de Soins Palliatifs Assistance Publique Hopitaux de Marseille"
            }, 
            "investigator": {
                "last_name": "sebastien salas, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.", 
        "other_outcome": [
            {
                "description": "raw values of pain levels (NPIS) at each evaluation time, percentage of reduction between the initial level of pain and other evaluation times", 
                "measure": "raw values of pain levels (NPIS)", 
                "safety_issue": "No", 
                "time_frame": "40 minutes"
            }, 
            {
                "description": "The tolerance to the treatment (lidocaine) will be assessed during the first 48 hours following the treatment administration. Adverse events will be cautiously collected (intensity and discomfort): i) lidocaine: arrhythmia, blurred vision, headache, malaise, tremors, metallic taste, nausea/vomiting, perioral numbness and tingling, sedation, and tinnitus.", 
                "measure": "tolerance to the treatments", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours"
            }
        ], 
        "overall_contact": {
            "email": "sebastien.salas@ap-hm.fr", 
            "last_name": "Sebastien SALAS, MD", 
            "phone": "+33491384408"
        }, 
        "overall_official": {
            "affiliation": "- Service d'Oncologie  M\u00e9dicale et de Soins Palliatifs Assistance Publique Hopitaux de Marseille", 
            "last_name": "Sebastien SALAS, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analgesic efficacy will be assessed from several endpoints. The primary endpoint will be defined as the change of pain level between baseline (T0) and 40 minutes (T1) after baseline. The pain level will be assessed using a self-administered numeric pain intensity scale (NPIS), ranged from 0 (no pain) to 10 (worst pain possible). A minimal 30% decrease of pain level between baseline and T1 will define the success, and other cases will define the failure of the treatment.", 
            "measure": "Analgesic efficacy", 
            "safety_issue": "No", 
            "time_frame": "40 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137954"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the intensity of the pain neuropathic component using the Neuropathic Pain Symptom Inventory (NPSI) at T4, T5, and T6 {Bouhassira, 2004 #9}; the NPSI is a 12-item self-administered questionnaire describing the intensity of the symptoms associated with pain neuropathic", 
            "measure": "intensity of the pain neuropathic", 
            "safety_issue": "No", 
            "time_frame": "120 minutes"
        }, 
        "source": "Assistance Publique Hopitaux De Marseille", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique Hopitaux De Marseille", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}